A share price of Globus Medical Inc [GMED] is currently trading at $83.42, up 1.74%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The GMED shares have gain 10.37% over the last week, with a monthly amount glided 17.18%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Globus Medical Inc [NYSE: GMED] stock has seen the most recent analyst activity on August 07, 2024, when Wells Fargo upgraded its rating to a Overweight and also boosted its price target to $78 from $60. Previously, Piper Sandler upgraded its rating to Overweight on May 20, 2024, and elevated its price target to $80. On March 18, 2024, upgrade upgraded it’s rating to Buy but maintained its price target of $60 on the stock. ROTH MKM started tracking the stock assigning a Buy rating and suggested a price target of $75 on October 20, 2023. Stifel upgraded its rating to a Buy but $61 remained the price target by the analyst firm on September 19, 2023. Canaccord Genuity upgraded its rating to Buy for this stock on March 30, 2023, but kept the price target unchanged to $67. In a note dated February 13, 2023, BofA Securities downgraded an Underperform rating on this stock and revised its target price from $83 to $63.
Globus Medical Inc experienced fluctuations in its stock price throughout the past year between $43.68 and $84.87. Currently, Wall Street analysts expect the stock to reach $79.54 within the next 12 months. Globus Medical Inc [NYSE: GMED] shares were valued at $83.42 at the most recent close of the market. An investor can expect a potential drop of -4.65% based on the average GMED price forecast.
Analyzing the GMED fundamentals
Trailing Twelve Months sales for Globus Medical Inc [NYSE:GMED] were 2.48B which represents 63.10% growth. Gross Profit Margin for this corporation currently stands at 0.55% with Operating Profit Margin at 0.07%, Pretax Profit Margin comes in at 0.05%, and Net Profit Margin reading is 0.04%. To continue investigating profitability, this company’s Return on Assets is posted at 0.02, Equity is 0.02 and Total Capital is 0.04. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.13.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 82.20 points at the first support level, and at 80.97 for the second support level. However, for the 1st resistance point, the stock is sitting at 84.08, and for the 2nd resistance point, it is at 84.73.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Globus Medical Inc [NYSE:GMED] is 2.51. As well, the Quick Ratio is 1.64, while the Cash Ratio is 0.76. Considering the valuation of this stock, the price to sales ratio is 4.58, the price to book ratio is 2.79 and price to earnings (TTM) ratio is 125.84.
Transactions by insiders
Recent insider trading involved Scavilla Daniel T, President, CEO, that happened on Nov 06 ’24 when 60000.0 shares were sold. SVP, GC, Corporate Secretary, Huller Kelly completed a deal on Nov 06 ’24 to sell 5000.0 shares. Meanwhile, Officer Scavilla Daniel T bought 60000.0 shares on Nov 06 ’24.
